Case | Histotypea | Stagingb |  | BLM | WRN | REQL | CBL | hMSH6 | hMSH3 | IGFIIR | TGF-βRII | BAX |
---|---|---|---|---|---|---|---|---|---|---|---|---|
No. | Â | Â | MSIc | (A)9 | (A)8 | (A)9 | (ATG)6 | (C)8 | (A)8 | (G)8 | (A)10 | (G)8 |
31R | I | I(T2N0M0) | 2/5 | - | - | - | - | - | - | - | - | - |
57R | I | IV(T3N1M1) | 5/5 | - | - | - | - | - | - | - | + | - |
63R | I | I(T2N0M0) | 5/5 | - | - | - | - | + | - | - | + | + |
67R | I | I(T2N0M0) | 4/5 | - | - | - | - | - | - | - | + | - |
69R | D | II(T3N0M0) | 4/5 | + | - | - | + | + | + | - | + | + |
79R | I | I(T2N0M0) | 5/5 | - | - | - | - | - | - | - | - | - |
3P | I | II(T3N0M0) | 4/7 | + | - | - | - | - | - | - | - | + |
11P | I | III(T3N1M0) | 3/7 | + | - | - | - | - | + | + | + | - |
14P | M | II(T3N0M0) | 6/7 | + | - | - | + | + | - | - | + | + |
17P | I | II(T3N0M0) | 3/7 | - | - | - | - | - | - | - | - | - |
19P | D | III(T3N1M0) | 3/7 | - | - | - | - | - | - | - | - | - |
27P | I | IV(T4N0M0) | 2/5 | - | - | - | - | - | - | - | + | - |
30P | I | I(T2N0M0) | 3/6 | - | - | - | - | - | - | - | - | - |
37P | I | I(T2N0M0) | 3/7 | - | - | - | - | - | - | - | + | - |
38P | I | III(T3N2M0) | 3/7 | - | - | - | - | - | - | - | + | - |
% | present study (number of cases) | 27% | 0% | 0% | 13% | 20% | 13% | 7% | 60% | 27% | ||
mutations | Â | Â | Â | (4/15) | (0/15) | (0/15) | (2/15) | (3/15) | (2/15) | (1/15) | (9/15) | (4/15) |
 | reported in literature (in GCs)d | - | - | - | - | 22–52% | 19–64% | 19–24% | 42–83% | 15–64% |